Canton Strategic Holdings, INC. (CNTN) — 8-K Filings

All 8-K filings from Canton Strategic Holdings, INC.. Browse 37 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (37)

8-K Filing — Mar 31, 2026
Tharimmune Inc. Board Shakeup: New Directors, CFO Appointed — Dec 12, 2025 Risk: medium
On December 10, 2025, Tharimmune, Inc. announced the departure of Dr. Jonathan T. Hunt from its Board of Directors. The company also elected Ms. Sarah E. Kelly
Tharimmune, Inc. Reports Board and Executive Compensation Changes — Nov 10, 2025 Risk: medium
Tharimmune, Inc. announced on November 7, 2025, changes related to its board of directors and executive compensation. Specifically, the company reported the dep
Tharimmune, Inc. Enters Material Definitive Agreement — Nov 7, 2025 Risk: medium
On November 6, 2025, Tharimmune, Inc. entered into a Material Definitive Agreement. The company, formerly known as Hillstream BioPharma Inc., is incorporated in
Tharimmune Announces Board Changes — Nov 6, 2025 Risk: medium
On November 3, 2025, Tharimmune, Inc. announced the departure of Dr. Jonathan T. Hunt from its Board of Directors. The company also announced the appointment of
Tharimmune, Inc. Files 8-K: Regulation FD Disclosure & Other Events — Nov 5, 2025 Risk: low
On November 3, 2025, Tharimmune, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing also includes financial statements a
Tharimmune, Inc. Files 8-K with Material Agreements and Equity Sales — Nov 3, 2025 Risk: medium
On November 3, 2025, Tharimmune, Inc. filed an 8-K report detailing several key events. The company entered into a material definitive agreement, engaged in unr
Tharimmune, Inc. Files 8-K with Bylaw Amendments — Oct 10, 2025 Risk: low
On October 10, 2025, Tharimmune, Inc. filed an 8-K report detailing amendments to its Articles of Incorporation or Bylaws and including financial statements and
Tharimmune, Inc. Files 8-K: Director Changes and Officer Compensation — Oct 9, 2025 Risk: medium
On October 9, 2025, Tharimmune, Inc. filed an 8-K report detailing several key events. The company announced the departure of Director Dr. Jonathan T. Hunt and
Tharimmune, Inc. Enters Material Definitive Agreement — Oct 6, 2025 Risk: medium
On October 1, 2025, Tharimmune, Inc. entered into a material definitive agreement. The company, formerly known as Hillstream BioPharma Inc., is incorporated in
Tharimmune, Inc. Relocates HQ, Reports Officer/Director Changes — Sep 8, 2025 Risk: low
Tharimmune, Inc. announced on September 2, 2025, a change in its principal executive offices to 34 Shrewsbury Avenue, Suite 1C, Red Bank, NJ 07701. This filing
Tharimmune, Inc. Files 8-K with Financials — Sep 5, 2025 Risk: low
Tharimmune, Inc. filed an 8-K on September 5, 2025, reporting other events and financial statements. The company, formerly known as Hillstream BioPharma Inc. un
Tharimmune Appoints New Chief Medical Officer — Aug 7, 2025 Risk: medium
On August 4, 2025, Tharimmune, Inc. announced the appointment of Dr. Jonathan P. S. Farber as Chief Medical Officer. Dr. Farber brings extensive experience in o
Tharimmune, Inc. Enters Material Definitive Agreement — Jul 31, 2025 Risk: medium
On July 25, 2025, Tharimmune, Inc. entered into a material definitive agreement. The company, formerly known as Hillstream BioPharma Inc., is incorporated in De
Tharimmune, Inc. Enters Material Definitive Agreement — Jul 28, 2025 Risk: medium
On July 23, 2025, Tharimmune, Inc. entered into a Material Definitive Agreement, the specifics of which are detailed in the filing. The company, formerly known
Tharimmune Announces Board and Executive Changes — Jun 24, 2025 Risk: medium
Tharimmune, Inc. announced on June 22, 2025, changes related to its board of directors and executive compensation. Specifically, the company reported the depart
Tharimmune, Inc. Files 8-K for Material Definitive Agreement — Jun 20, 2025 Risk: medium
On June 13, 2025, Tharimmune, Inc. entered into a Material Definitive Agreement. The company, formerly known as Hillstream BioPharma Inc., is incorporated in De
Tharimmune Appoints New Directors and Officers, Adjusts Compensation — Jun 16, 2025 Risk: medium
Tharimmune, Inc. announced on June 10, 2025, changes in its board of directors and executive compensation. Specifically, the company elected two new directors,
Tharimmune Announces Board Changes and New CFO — Jun 11, 2025 Risk: medium
Tharimmune, Inc. announced on June 11, 2025, the departure of Dr. Jonathan T. Hunt from its Board of Directors. The company also elected two new directors, Dr.
Tharimmune, Inc. Files 8-K on Security Holder Votes — Jun 10, 2025 Risk: low
Tharimmune, Inc. filed an 8-K on June 10, 2025, reporting on matters submitted to a vote of its security holders. The filing details the company's corporate str
Tharimmune Board Changes and Officer Compensation — May 9, 2025 Risk: low
Tharimmune, Inc. announced on May 9, 2025, a change in its board of directors. Specifically, Dr. Jonathan M. Roth, a director, has resigned. The company also re
Tharimmune, Inc. Reports Executive and Director Changes — Apr 28, 2025 Risk: medium
On April 28, 2025, Tharimmune, Inc. filed an 8-K report detailing changes in its executive and director positions. The filing indicates the election of new dire
Tharimmune, Inc. Updates Corporate Address and Contact Info — Apr 25, 2025 Risk: low
On April 24, 2025, Tharimmune, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 1200 Route 22 East, Suite
Tharimmune Appoints New CMO, Board Member — Apr 10, 2025 Risk: medium
On April 9, 2025, Tharimmune, Inc. announced changes to its board of directors, including the appointment of Dr. Jonathan P. S. Farber as Chief Medical Officer
Tharimmune Faces Delisting Concerns — Apr 4, 2025 Risk: high
Tharimmune, Inc. filed an 8-K on April 1, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company, formerly known as H
Tharimmune, Inc. Files 8-K on Director Changes — Feb 27, 2025 Risk: medium
On February 21, 2025, Tharimmune, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing indic
Tharimmune, Inc. Files 8-K: Material Agreement, Other Events — Dec 6, 2024 Risk: medium
On December 5, 2024, Tharimmune, Inc. entered into a Material Definitive Agreement, the specifics of which are detailed within the filing. The company also repo
Tharimmune Board Changes and Officer Compensation — Nov 21, 2024 Risk: low
Tharimmune, Inc. announced on November 20, 2024, a change in its board of directors. Dr. Jonathan M. Roth, who served as a director, has resigned. The company a
Tharimmune Files 8-K with Regulatory Updates — Sep 30, 2024 Risk: low
Tharimmune, Inc. filed an 8-K on September 30, 2024, reporting on various events including Regulation FD disclosures, other events, and financial statements. Th
Tharimmune, Inc. Files 8-K: Material Definitive Agreement — Sep 16, 2024 Risk: medium
On September 11, 2024, Tharimmune, Inc. entered into a Material Definitive Agreement. The filing also includes Regulation FD Disclosure and Financial Statements
Tharimmune, Inc. Files 8-K with Material Agreement — Jun 20, 2024 Risk: medium
On June 18, 2024, Tharimmune, Inc. entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. The company also r
Tharimmune to Acquire Bio-Genetics for $1.5M — Jun 11, 2024 Risk: medium
Tharimmune, Inc. announced on June 11, 2024, that it has entered into a definitive agreement to acquire all outstanding equity interests in Bio-Genetics, Inc. f
Tharimmune, Inc. Files Material Definitive Agreement 8-K — Jun 7, 2024 Risk: medium
On June 7, 2024, Tharimmune, Inc. filed an 8-K report detailing a material definitive agreement. The company, formerly known as Hillstream BioPharma Inc., is in
Tharimmune Files 8-K: Corporate Updates & Financials — May 22, 2024 Risk: low
Tharimmune, Inc. filed an 8-K on May 22, 2024, reporting amendments to its Articles of Incorporation or Bylaws, other events, and financial statements/exhibits.
Tharimmune, Inc. Files 8-K on Security Holder Votes — May 14, 2024 Risk: low
Tharimmune, Inc. filed an 8-K on May 14, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific details ab
Tharimmune, Inc. Files 8-K with Corporate Updates — Mar 11, 2024 Risk: low
On March 7, 2024, Tharimmune, Inc. filed an 8-K report detailing amendments to its Articles of Incorporation and the filing of financial statements and exhibits
Tharimmune Updates Business Address and Phone Number — Feb 8, 2024 Risk: low
Tharimmune, Inc. filed an 8-K on February 8, 2024, to update its business address to 1200 Route 22 East, Suite 2000, Bridgewater, NJ 08807, and its telephone nu

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX